scholarly journals The theory of modulated hormone therapy for the treatment of breast cancer in pre- and post-menopausal women

AIP Advances ◽  
2012 ◽  
Vol 2 (1) ◽  
pp. 011206 ◽  
Author(s):  
Teresa S. Wiley ◽  
Jason T. Haraldsen
Keyword(s):  
Breast Cancer ◽  
Hormone Therapy ◽  
Menopausal Women ◽  
Post Menopausal

scholarly journals Risk of Breast Cancer by Type of Menopausal Hormone Therapy: a Case-Control Study among Post-Menopausal Women in France

PLoS ONE ◽  
2013 ◽  
Vol 8 (11) ◽  
pp. e78016 ◽  
Author(s):  
Emilie Cordina-Duverger ◽  
Thérèse Truong ◽  
Antoinette Anger ◽  
Marie Sanchez ◽  
Patrick Arveux ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Hormone Therapy ◽  
Case Control Study ◽  
Case Control ◽  
Menopausal Hormone Therapy ◽  
Menopausal Women ◽  
Post Menopausal ◽  
Control Study

HORMONE THERAPY IN METASTATIC BREAST CANCER: CLINICAL RESPONSE AND URINARY GONADOTROPHINS

1965 ◽  
Vol 50 (3) ◽  
pp. 345-356
Author(s):  
J. G. Stewart ◽  
L. G. Skinner ◽  
P. J. O'Connor
Keyword(s):  
Breast Cancer ◽  
Hormone Therapy ◽  
Clinical Response ◽  
Metastatic Breast ◽  
Site Specificity ◽  
Metastatic Breast Carcinoma ◽  
Remission Period ◽  
Menopausal Women ◽  
Pre Treatment ◽  
Post Menopausal

ABSTRACT The total urinary gonadotrophin output of a group of post menopausal women with metastatic breast carcinoma undergoing hormone therapy, which in every case initially consisted of treatment with diethylstilboestrol, DES (ca. 20 mg/d), has been studied for periods varying from seven months to 3½ years. No correlation between gonadotrophin output and clinical response was found, except that in all cases showing objective regression urinary gonadotrophin remained low throughout the remission period. A low level of gonadotrophin output was not, however, necessarily indicative of a good clinical remission. Following withdrawal of DES, and independent of the period of therapy, recovery to pre-treatment levels was the rule rather than the exception. A small group of patients maintained on a lower dose of DES (3–5 mg/d) showed the same degree of suppression of urinary output as those receiving 20 mg/d, and several of these exhibited objective remissions. The study has emphasised the importance of site specificity in the response to hormone therapy, and underlines the difficulties of relating the clinical response of the patient as a whole to changes in hormonal environment.

scholarly journals 82P Risk factors for breast cancer: A case-control study among post-menopausal women in Pakistan

2016 ◽  
Vol 27 ◽  
pp. ix24
Author(s):  
N.A. Jadoon ◽  
M. Hussain ◽  
F.U. Sulehri ◽  
A. Zafar ◽  
A. Ijaz
Keyword(s):  
Breast Cancer ◽  
Risk Factors ◽  
Case Control Study ◽  
Case Control ◽  
Menopausal Women ◽  
Post Menopausal ◽  
Control Study

scholarly journals Endogenous hormones and risk of invasive breast cancer in pre- and post-menopausal women: findings from the UK Biobank

2021 ◽  
Author(s):  
Sandar Tin Tin ◽  
Gillian K. Reeves ◽  
Timothy J. Key
Keyword(s):  
Breast Cancer ◽  
Breast Cancer Risk ◽  
Cancer Risk ◽  
Invasive Breast Cancer ◽  
Cox Regression ◽  
Menopausal Status ◽  
Endogenous Hormones ◽  
Uk Biobank ◽  
Menopausal Women ◽  
Post Menopausal

Abstract Background Some endogenous hormones have been associated with breast cancer risk, but the nature of these relationships is not fully understood. Methods UK Biobank was used. Hormone concentrations were measured in serum collected in 2006–2010, and in a repeat subsample (N ~ 5000) in 2012–13. Incident cancers were identified through data linkage. Cox regression models were used, and hazard ratios (HRs) corrected for regression dilution bias. Results Among 30,565 pre-menopausal and 133,294 post-menopausal women, 527 and 2,997, respectively, were diagnosed with invasive breast cancer during a median follow-up of 7.1 years. Cancer risk was positively associated with testosterone in post-menopausal women (HR per 0.5 nmol/L increment: 1.18; 95% CI: 1.14, 1.23) but not in pre-menopausal women (pheterogeneity = 0.03), and with IGF-1 (insulin-like growth factor-1) (HR per 5 nmol/L increment: 1.18; 1.02, 1.35 (pre-menopausal) and 1.07; 1.01, 1.12 (post-menopausal); pheterogeneity = 0.2), and inversely associated with SHBG (sex hormone-binding globulin) (HR per 30 nmol/L increment: 0.96; 0.79, 1.15 (pre-menopausal) and 0.89; 0.84, 0.94 (post-menopausal); pheterogeneity = 0.4). Oestradiol, assessed only in pre-menopausal women, was not associated with risk, but there were study limitations for this hormone. Conclusions This study confirms associations of testosterone, IGF-1 and SHBG with breast cancer risk, with heterogeneity by menopausal status for testosterone.

scholarly journals Tamoxifen and oxidative stress: an overlooked connection

2021 ◽  
Vol 12 (1) ◽  
Author(s):  
Nermin S. Ahmed ◽  
Marek Samec ◽  
Alena Liskova ◽  
Peter Kubatka ◽  
Luciano Saso
Keyword(s):  
Breast Cancer ◽  
Oxidative Stress ◽  
Gold Standard ◽  
Pharmacological Activities ◽  
Standard Drug ◽  
Menopausal Women ◽  
Wide Range ◽  
Post Menopausal ◽  
Apoptotic Effects ◽  
And Oxidative Stress

AbstractTamoxifen is the gold standard drug for the treatment of breast cancer in pre and post-menopausal women. Its journey from a failing contraceptive to a blockbuster is an example of pharmaceutical innovation challenges. Tamoxifen has a wide range of pharmacological activities; a drug that was initially thought to work via a simple Estrogen receptor (ER) mechanism was proven to mediate its activity through several non-ER mechanisms. Here in we review the previous literature describing ER and non-ER targets of tamoxifen, we highlighted the overlooked connection between tamoxifen, tamoxifen apoptotic effects and oxidative stress.

Prognostic Signicance of Cellular Iron Metabolism in Breast Cancer

2018 ◽  
Vol 1 (1) ◽  
Author(s):  
Rizwan Ullah Khan ◽  
Amber Hassan ◽  
Imrana Tanvir ◽  
Kashifa Ehsan
Keyword(s):  
Breast Cancer ◽  
Breast Carcinoma ◽  
Ki 67 ◽  
Luminal B ◽  
Cellular Iron ◽  
Menopausal Women ◽  
New Strategy ◽  
Poorly Differentiated ◽  
Well Differentiated ◽  
Post Menopausal

Breast carcinoma is among the most common malignancy in women. Abstract:Original ArticleAim of the present study was to evaluate the prognostic signicance of iron expression in the biopsies of patients with breast cancer Objective:24 breast biopsies were studied. 19 cases were poorly differentiated, 5 cases were moderately differentiated and there was no well differentiated case. Iron, Estrogen receptor (ER), Progesterone receptor (PR), HER2 and Ki-67 immunohistochemical staining was performed for all these cases. Methods: Among the 5 moderately differentiated cases, 3 (60%) were positive for iron staining and among 19 poorly differentiated cases, 11 cases (57.89%) were positive. More iron positive cases (7 out of 14) were triple positive belonging to Luminal B class. Out of 14 iron positive cases, 11 were positive for HER2, 10 for ER, 9 for PR and all positive for Ki-67. Results: Iron deciency in premenopausal and overload in post-menopausal women can contribute to the development of breast carcinoma. So, iron can be considered as a cheap and effective marker for the prognosis of breast cancer. Association between a rise in iron levels and HER2 expression may provide new strategy for breast cancer treatment.

Sign in / Sign up

Export Citation Format

Share Document